We are monitoring the impact of COVID-19 on North America Hemophilia Management Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 271
Share on
Share on

North America Hemophilia Management Market Research Report – Segmented By Type, Drug & By Country (The U.S., Canada & Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 271
Pages: 143

North America Hemophilia Management Market Size (2021 to 2026)

As per the report, the size of the Hemophilia Management Market in North America was worth USD 1.90 billion in 2021 and estimated to be growing at a CAGR of 1.52%, to reach USD 2.05 billion by 2026. Hemophilia is a genetic disorder that impairs the body`s ability to control blood clotting.

The rising population with the growing incidences of hemophilia among the people in the North American region is majorly driving the North American hemophilia management market growth. This occurs due to a lack of sufficient blood-clotting proteins in the body which is also caused due to deficiency of factor VIII. The occurrence rate of this disease is more in males as compared to females. As the current number of males living in the United States with Hemophilia is expected to be between 30,000 and 33,000, its prevalence is 12 cases per 1 lakh males for hemophilia A and 3.7 cases per 1 lakh males for Hemophilia B.

Also, the technological advancements for developing new and effective treatments and devices for detecting curative agents are expected to uplift the market growth. On the other hand, the rising demand and use of prophylactic therapy to treat hemophilia increase the demand for hemophilia management. In addition, other factors such increase in the awareness among the people for the medications and treatment available in the market for treating hemophilia are expected to propel hemophilia management.

Furthermore, the increase in fundings and investments from government and non-government firms in research and development activities for developing effective drugs and treatment for treating hemophilia is increasing the demand for hemophilia management in the market. In addition, an increase in the initiatives for developing medical and health care awareness among the people in the region is increasing the growth of the North American hemophilia management market.

However, the high costs of the drugs and treatment procedures for hemophilia with the presence of alternative treatments and medications available in the market are hampering the market growth. Furthermore, the stringent government rules and regulations with strict approval policies also affect the market growth. In addition, the lack of awareness about the disease among the people, side effects and allergies associated with the treatment and the products, the limited access to the medications and the therapies are limiting the growth of hemophilia management in the market.

This research report on the North American hemophilia management market has been segmented and sub-segmented into the following categories:

By Type:

  • Hemophilia A
  • Hemophilia B

By Drug:

  • Octocogalfa
  • Nonacogalfa
  • Desmopressin
  • Other Drugs

By Country:

  • United States
  • Canada
  • Rest of North America

Regionally, North America was the largest market for hemophilia management, accounting for a significant share in the global market in 2020. In North America, the United States is the largest market for hemophilia management due to high government support and the increasing number of hemophilia patients. Canada is estimated to be the fastest-growing region due to high growth potential due to the growing usage of available medication.

The U.S. is currently dominating the market in the North American region, and it is likely to continue its growth during the forecast period. The market growth is fuelled by an increase in the demand for prophylaxis treatment and other available treatments, the availability of effective therapies, and advanced infrastructure.

The Canadian market is forecasted to see a healthy growth rate during the forecast period due to increased initiatives and investment by government and non-government organizations in research and development activities to improve the efficacy of hemophilia treatments and increase public awareness.


A few notable companies in the North American hemophilia management market profiled in this report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma, and Swedish Orphan Biovitrum AB.

  1. Introduction

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

  1. Research Methodology

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

  1. Overview

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

  1. Market Segmentation

                5.1 BY Type                                        

                                5.1.1 Hemophilia A                         

                                5.1.2 Hemophilia B                         

                5.2 By Drug                                        

                                5.2.1 Octocogalfa                            

                                5.2.2 Nonacogalfa                           

                                5.2.3 Desmopressin                       

                                5.2.4 Other drugs                            

  1. Geographical Analysis

                                6.1 Introduction                              

                                6.2 United States                            

                                6.3 Canada                         

  1. Strategic Analysis

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                      

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services               

                                7.2.5 Competitive Rivalry within the Industry                      

  1. Market Leaders' Analysis

                8.1 Biogen                                          

                                8.1.1 Overview                

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                            

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Pfizer Inc.                                    

                8.3 Baxter International Inc.                                       

                8.4 Bayer Pharma AG                                    

                8.5 Novo Nordisk A/S                                    

                8.6 Grifols International SA                                         

                8.7 CSL Behring                                

                8.8 Octapharma                                               

                8.9 Swedish Orphan Biovitrum AB                                            

  1. Competitive Landscape

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                        

                9.3 Agreements, collaborations and Joint Ventures                                          

                9.4 New Product Launches                                          

  1. Expert Opinions

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 


a) List of Tables

b) List of Figures

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Hemophilia Management Market By Region, From 2021 to 2026 (USD Billion)           
  2. North America Hemophilia Management Market By Type, From 2021 to 2026 (USD Billion)         
  3. North America Hemophilia-A Market By Region, From 2021 to 2026 (USD Billion)                                                  
  4. North America Hemophilia-B Market By Region, From 2021 to 2026 (USD Billion)                                                  
  5. North America Hemophilia Management Market By Drug, From 2021 to 2026 (USD Billion)
  6. North America Octocogalfa Market By Region, From 2021 to 2026 (USD Billion)                                                      
  7. North America Nonacogalfa Market By Region, From 2021 to 2026 (USD Billion)                                                     
  8. North America Desmopressin Market By Region, From 2021 to 2026 (USD Billion)                                                 
  9. North America Other drugs Market By Region, From 2021 to 2026 (USD Billion)                                                      
  10. United States Hemophilia Management Market By Type, From 2021 to 2026 (USD Billion)                 
  11. United States Hemophilia Management Market By Drug, From 2021 to 2026 (USD Billion) 
  12. Canada Hemophilia Management Market By Type, From 2021 to 2026 (USD Billion)
  13. Canada Hemophilia Management Market By Drug, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports


$ 1234 3335

Click for Request Sample